[Retracted] Protumor Effects of Histone H3–H4 Chaperone Antisilencing Feature 1B Gene on Lung Adenocarcinoma: In Silico and In Vitro Analyses

Table 3

Clinical characteristics of the TCGA-LUAD patients in low and high ASF1B gene. Expression level groups.

Characteristic	Low expression of ASF1B	High expression of ASF1B
	267	268
T stage, (%)			0.018
T1	104 (19.5%)	71 (13.3%)
T2	129 (24.2%)	160 (30.1%)
T3	22 (4.1%)	27 (5.1%)
T4	10 (1.9%)	9 (1.7%)
N stage, (%)			0.007
N0	187 (36%)	161 (31%)
N1	36 (6.9%)	59 (11.4%)
N2	31 (6%)	43 (8.3%)
N3	0 (0%)	2 (0.4%)
M stage, (%)			0.104
M0	184 (47.7%)	177 (45.9%)
M1	8 (2.1%)	17 (4.4%)
Pathologic stage, (%)			0.002
Stage I	167 (31.7%)	127 (24.1%)
Stage II	50 (9.5%)	73 (13.9%)
Stage III	35 (6.6%)	49 (9.3%)
Stage IV	9 (1.7%)	17 (3.2%)
Primary therapy outcome, (%)			0.038
PD	25 (5.6%)	46 (10.3%)
SD	20 (4.5%)	17 (3.8%)
PR	3 (0.7%)	3 (0.7%)
CR	178 (39.9%)	154 (34.5%)
Gender, (%)			0.241
Female	150 (28%)	136 (25.4%)
Male	117 (21.9%)	132 (24.7%)
Race, (%)			0.936
Asian	3 (0.6%)	4 (0.9%)
Black or African-American	28 (6%)	27 (5.8%)
White	210 (44.9%)	196 (41.9%)
Age, (%)			0.028
≤65	115 (22.3%)	140 (27.1%)
>65	144 (27.9%)	117 (22.7%)
Residual tumor, (%)			0.220
R0	168 (45.2%)	187 (50.3%)
R1	6 (1.6%)	7 (1.9%)
R2	0 (0%)	4 (1.1%)
Anatomic neoplasm subdivision, (%)			0.802
Left	104 (20%)	101 (19.4%)
Right	155 (29.8%)	160 (30.8%)
Anatomic neoplasm subdivision 2, (%)			0.415
Central lung	31 (16.4%)	31 (16.4%)
Peripheral lung	54 (28.6%)	73 (38.6%)
number_pack_years_smoked, (%)			0.106
<40	102 (27.6%)	86 (23.3%)
≥40	82 (22.2%)	99 (26.8%)
Smoker, (%)			0.709
No	35 (6.7%)	40 (7.7%)
Yes	222 (42.6%)	224 (43%)
OS event, (%)			0.006
Alive	187 (35%)	156 (29.2%)
Dead	80 (15%)	112 (20.9%)
DSS event, (%)			0.002
Alive	204 (40.9%)	175 (35.1%)
Dead	44 (8.8%)	76 (15.2%)
PFI event, (%)			0.031
Alive	167 (31.2%)	142 (26.5%)
Dead	100 (18.7%)	126 (23.6%)
Age, median (IQR)	67 (60, 74)	64 (57, 71)	0.002